Germline BRCA2 mutations and management of mCRPC

A newly published paper in the Journal of Clinical Oncology has confirmed — based on a prospective study (as opposed to retrospective data) — that there is a strong risk association between a germline mutation of the BRCA2 gene and risk for metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …

Maybe coming soon to a medical center near you?

Our regular readers will remember that we have commented on and off on the development of different types of system that (maybe) can be used to test for risk of cancer based on smell … an ability that has been clearly demonstrated among certain trained dogs and one of two electronic systems. … READ MORE …

A poorly informed public and risk for cancer

A recent report from the Prostate Cancer Foundation (PCF), here in the US, found — unsurprisingly to your sitemaster, at least — that the average American remains very poorly informed about risk for prostate cancer and associated issues. … READ MORE …

But annual, mass, population-based PSA screening really works (or does it?)

A new and potentially controversial article in Urology (the “Gold Journal”) has just suggested that regular, mass, population-based screening of men for risk of prostate cancer every 12 to 18 months remains a good idea. … READ MORE …

It’s Prostate Cancer Awareness Month, again …

… and during Prostate Cancer Awareness Month men and their families are regularly subjected to messaging about the importance of getting “screened” for risk of prostate cancer. … READ MORE …

“Is prostate cancer screening right for you?”

The following infographic was also issued today by the U.S. Preventive Services Task Force (USPSTF) and offers guidance as to the appropriateness of prostate cancer screening for an average, 55- to 69-year-old American male with no specific, known risk factors for prostate cancer: … READ MORE …

USPSTF releases new guidance about prostate cancer screening

Earlier today, the US Preventive Services Task Force (USPSTF) issued the final version of its revised guidance on screening for risk of prostate cancer. … READ MORE …